Rating #12
Stanley Freeman Druckenmiller
Duquesne Family Office
Portfolio value
Stocks
Performance
1 Year
+24.24%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Stanley Freeman Druckenmiller’s Portfolio: Q3 2025
Top10 stocks: 53.93% of the portfolio
Stanley Freeman Druckenmiller’s Trades: Q3 2025
Adds
New Buys
Sold Outs
Cuts
2.36ppt
0.65ppt
0.86ppt
0.52ppt
0.98ppt
0.62ppt
0.56ppt
0.47ppt
0.62ppt
0.54ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  AMZN | +100.00% | $226.35 | $98.93M | 2.36ppt | |
2  TWLO | +155.79% | $112.58 | $35.16M | 0.65ppt | |
3  BAC | +189.34% | $48.79 | $31.58M | 0.86ppt | |
4  DOCU | +30.65% | $77.06 | $30.48M | 0.52ppt | |
5  NAMS | +131.17% | $23.97 | $26.16M | 0.98ppt | |
6  WAB | +77.36% | $197.36 | $26.03M | 0.62ppt | |
7  QSR | +50.65% | $65.79 | $25.02M | 0.56ppt | |
8  CRS | +73.76% | $255.72 | $23.88M | 0.47ppt | |
9  LEN | +210.82% | $124.12 | $23.52M | 0.62ppt | |
10  TBBB | +228.14% | $25.99 | $21.38M | 0.54ppt |
Stanley Freeman Druckenmiller’s Holdings: Q3 2025
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
1  NTRA | Medical Laboratories | $99.19 | +4.19% | 3.21M | $517.44M | 12.74% -0.06ppt | 2.36% | 13 Quarters | Q3 2025 | |
2  INSM | Pharmaceutical Pres | $88.13 | +7.54% | 2.42M | $349.00M | 8.59% 3.02ppt | 1.28% | 6 Quarters | Q3 2025 | |
3  TEVA | Pharmaceutical Pres | $18.91 | +3.91% | 16.59M | $335.20M | 8.25% 1.68ppt | 1.45% | 5 Quarters | Q3 2025 | |
4  TSM | Semiconductors | $181.79 | 0.00% | 765.09K | $213.68M | 5.26% 1.00ppt | 0.01% | 5 Quarters | Q2 2025 | |
5  WWD | Industrial Apparatus | $150.85 | -25.43% | 633.02K | $159.97M | 3.94% -1.17ppt | 1.06% | 8 Quarters | Q3 2025 | |
6  CPNG | Retail-Catalog & Mail-Order | $33.90 | +12.85% | 4.63M | $149.19M | 3.67% 0.65ppt | 0.26% | 19 Quarters | Q3 2025 | |
7  MELI | Other Business Services | $1756.50 | +8.60% | 58.34K | $136.35M | 3.36% -0.09ppt | 0.12% | 6 Quarters | Q3 2025 | |
8 DOCU | Prepackaged Software | $78.77 | +30.65% | 1.69M | $121.54M | 2.99% 0.52ppt | 0.83% | 3 Quarters | Q3 2025 | |
Pharmaceutical Pres | $36.29 | 0.00% | 1.00M | $106.93M | 2.63% 0.30ppt | 1.17% | 5 Quarters | Q1 2025 | ||
10 I EEM | - | $53.40 | +100.00% | 1.90M | $101.46M | 2.50% 2.50ppt | 0.50% | 1 Quarter | Q3 2025 | |
11 AMZN | Retail-Catalog & Mail-Order | $219.57 | +100.00% | 437.07K | $95.97M | 2.36% 2.36ppt | 0.00% | 4 Quarters | Q3 2025 | |
12  ROKU | Cable & Pay TV Services | $80.06 | -25.27% | 822.44K | $82.35M | 2.03% -0.35ppt | 0.56% | 3 Quarters | Q3 2025 | |
13 F FIGR | Loan Brokers | $36.37 | +100.00% | 2.12M | $76.99M | 1.90% 1.90ppt | 1.02% | 1 Quarter | Q3 2025 | |
14 QSR | Eating places | $65.57 | +50.65% | 1.13M | $72.57M | 1.79% 0.56ppt | 0.34% | 2 Quarters | Q3 2025 | |
15 S STUB | - | $16.84 | +100.00% | 4.26M | $71.73M | 1.77% 1.77ppt | 1.16% | 1 Quarter | Q3 2025 | |
16 WAB | Railroad Equipment | $180.97 | +77.36% | 302.41K | $60.62M | 1.49% 0.62ppt | 0.18% | 7 Quarters | Q3 2025 | |
17 S SPY Call | - | $617.85 | 0.00% | 90.00K | $59.96M | 1.48% 0.11ppt | - | 2 Quarters | Q2 2025 | |
18  META | Computer Programming & Data | $734.38 | +100.00% | 76.10K | $55.89M | 1.38% 1.38ppt | 0.00% | 1 Quarter | Q3 2025 | |
19 NAMS | Pharmaceutical Pres | $24.37 | +131.17% | 1.92M | $54.71M | 1.35% 0.98ppt | 1.71% | 5 Quarters | Q3 2025 | |
20 I IWM Call | - | $215.79 | -32.54% | 226.00K | $54.68M | 1.35% -0.43ppt | - | 2 Quarters | Q3 2025 |
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.